Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current Medicinal Chemistry

• Publication date

  2009-09-30

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/092986709789177993PMID 19747136
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators.

  2009cited by this paper
• Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators.

  2009cited by this paper
• Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators.

  2009cited by this paper
• Inflammation and insulin resistance

  2008cited by this paper
• Glucokinase activators in diabetes management

  2008cited by this paper
• SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.

  2008cited by this paper
• Glucokinase activators for the potential treatment of type 2 diabetes.

  2008cited by this paper
• Glucose modulation of glucokinase activation by small molecules

  2008cited by this paper
• Update in type 1 diabetes.

  2007cited by this paper
• Glucokinase activators: molecular tools for studying the physiology of insulin-secreting cells.

  2007cited by this paper
• Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions

  2007cited by this paper
• Glucose-Dependent Modulation of Insulin Secretion and Intracellular Calcium Ions by GKA50, a Glucokinase Activator

  2007cited by this paper
• Design of a potent, soluble glucokinase activator with excellent in vivo efficacy.

  2006cited by this paper
• The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy.

  2006cited by this paper
• Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats

  2006cited by this paper
• An Allosteric Activator of Glucokinase Impairs the Interaction of Glucokinase and Glucokinase Regulatory Protein and Regulates Glucose Metabolism*

  2006cited by this paper
• Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy.

  2006cited by this paper
• The metabolic syndrome: prevalence, CHD risk, and treatment.

  2006cited by this paper
• Islet beta cell failure in type 2 diabetes.

  2006cited by this paper
• Type 2 diabetes market

  2005cited by this paper
• Glucokinase-activating ureas.

  2005cited by this paper
• A novel glucokinase activator modulates pancreatic islet and hepatocyte function.

  2005cited by this paper
• Inflammatory, atherothrombotic aspects of type 2 diabetes

  2005cited by this paper
• Targeting glucokinase activation for the treatment of type 2 diabetes--a status review.

  2005cited by this paper
• Discovery, synthesis and biological evaluation of novel glucokinase activators.

  2005cited by this paper
• Macrovascular complications of metabolic syndrome: an early intervention is imperative.

  2004cited by this paper
• Obesity, insulin resistance, and cardiovascular disease.

  2004cited by this paper
• Prevention of type 2 diabetes: insulin resistance and beta-cell function.

  2004cited by this paper
• Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase.

  2004cited by this paper
• Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators.

  2004cited by this paper
• Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat.

  2004cited by this paper
• Genetic cause of hyperglycaemia and response to treatment in diabetes.

  2003cited by this paper
• Glucokinase (GCK) mutations in hyper‐ and hypoglycemia: Maturity‐onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy

  2003cited by this paper
• Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy

  2003cited by this paper
• The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.

  2002cited by this paper
• Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor.

  2002cited by this paper
• Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes.

  2002cited by this paper
• Evidence that glucokinase regulatory protein is expressed 
and interacts with glucokinase in rat brain

  2002cited by this paper
• beta-cell glucotoxicity in the Psammomys obesus model of type 2 diabetes.

  2001cited by this paper
• Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover.

  2001cited by this paper
• Brain glucose-sensing mechanisms: ubiquitous silencing by aglycemia vs. hypothalamic neuroendocrine responses.

  2001cited by this paper
• New drug targets for type 2 diabetes and the metabolic syndrome

  2001cited by this paper
• Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats

  2000cited by this paper
• Localization of glucokinase gene expression in the rat brain.

  2000cited by this paper
• Insulin resistance: current concepts.

  1998cited by this paper
• Glucose effectiveness assessed under dynamic and steady state conditions. Comparability of uptake versus production components.

  1997cited by this paper
• Pathophysiology of insulin resistance in human disease.

  1995cited by this paper
• Mammalian glucokinase.

  1993cited by this paper
• A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phosphate and fructose 1-phosphate.

  1989cited by this paper
• Structural evaluation of glucose analogues on feeding elicitation in rat.

  1989cited by this paper
• The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM

  1988cited by this paper
• D-glucose suppression of eating after intra-third ventricle infusion in rat.

  1986cited by this paper
• New perspectives on pancreatic islet glucokinase.

  1984cited by this paper

• Synthesis, characterization, DFT, and molecular docking of 1,2,3,4-tetrahydro-isoquinoline/4-phenylpiperazine-sulfonyl benzamide derivatives as possible antidiabetic agents

  2025cites this paper
• Insights to the emerging potential of glucokinase activators as antidiabetic agent.

  2024cites this paper
• Identification of small-molecule glucokinase activator for type-2-diabetes treatment: a structure-based virtual screening approach

  2023cites this paper
• Molecular docking, 2D-QSAR and ADMET studies of 4-sulfonyl-2-pyridone heterocycle as a potential glucokinase activator

  2023cites this paper
• An Insight into the Development of Potential Antidiabetic Agents along with their Therapeutic Targets.

  2023cites this paper
• Antidiabetic and antihyperlipidemic effects of crude fractions and isolated compound from Striga orobanchioides Benth on streptozotocin induced diabetic rats

  2022cites this paper
• Anti-diabetes Research in India: Contributions from Industrial Organizations

  2021cites this paper
• Design and synthesis of newer N-benzimidazol-2yl benzamide analogues as allosteric activators of human glucokinase

  2021cites this paper
• Investigation of phytoconstituents of Enicostemma littorale as potential glucokinase activators through molecular docking for the treatment of type 2 diabetes mellitus

  2021cites this paper
• Design, synthesis, and evaluation of some novel N-benzothiazol-2-yl benzamide derivatives as allosteric activators of human glucokinase

  2021cites this paper
• Recent Developments in Medicinal Chemistry of Allosteric Activators of Human Glucokinase for Type 2 Diabetes Mellitus Therapeutics.

  2020cites this paper
• IN SILICO DOCKING STUDIES OF COMPOUNDS FROM PERSIAN SHALLOT AS ALLOSTERIC GLUCOKINASE ACTIVATORS

  2020cites this paper
• Emerging technologies in pediatrics: the paradigm of neonatal diabetes mellitus

  2020cites this paper
• Molecular Docking Investigation of Compounds from Sapium Ellipticum (Hochst) Pax as Allosteric Activators of Human Glucokinase

  2019cites this paper
• Design, synthesis and evaluation of novel 3,5-disubstituted benzamide derivatives as allosteric glucokinase activators

  2019cites this paper
• Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators

  2018cites this paper
• Octanoic acid potentiates glucose-stimulated insulin secretion and expression of glucokinase through the olfactory receptor in pancreatic β-cells.

  2018cites this paper
• N‐pyridin‐2‐yl benzamide analogues as allosteric activators of glucokinase: Design, synthesis, in vitro, in silico and in vivo evaluation

  2018cites this paper
• Design, Synthesis and Antidiabetic Activity of Novel Sulfamoyl Benzamide Derivatives as Glucokinase Activators

  2018cites this paper
• In situ Monitoring of a Heterogeneous Etherification Reaction Using Quantitative Raman Spectroscopy

  2015cites this paper
• Construction of phenoxazine rings containing nitro and sulfonic acid groups leading to phenoxazine-3-sulfonamide derivatives: their evaluation as novel and potential insulin secretagogues

  2014cites this paper
• Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.

  2014cites this paper
• Ultrasound-based approach to spiro-2,3-dihydroquinazolin-4(1H)-ones: their in vitro evaluation against chorismate mutase

  2013cites this paper
• Antidiabetic agents: past, present and future.

  2013cites this paper
• Sex differences in insulin resistance in GABAB1 knockout mice.

  2013cites this paper
• GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?

  2013cites this paper
• H3PO4/(CF3CO)2O Mediated Acylation Followed by Hurd–Mori Reaction: Synthesis of Novel 1,2,3‐Thiadiazol Derivatives

  2013cites this paper
• Multikilogram Synthesis of a Hepatoselective Glucokinase Activator

  2012cites this paper
• Molecular docking assessment of pyridone derivatives as glucokinase activators

  2012cites this paper
• Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase.

  2012cites this paper
• Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators.

  2012cites this paper
• Reduced expression of the LRP16 gene in mouse insulinoma (MIN6) cells exerts multiple effects on insulin content, proliferation and apoptosis

  2012cites this paper
• Promoting stone fruits for Protection against the Metabolic Syndrome

  2012cites this paper
• Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes

  2012cites this paper
• N-heterocyclic carbene-mediated hydroacylation-Sonogashira/Heck/Suzuki coupling in a single pot: a new cascade reaction.

  2012cites this paper
• Reduced expression of the LRP16 gene in mouse insulinoma (MIN6) cells exerts multiple effects on insulin content, proliferation and apoptosis

  2012cites this paper
• General and scalable amide bond formation with epimerization-prone substrates using T3P and pyridine.

  2011cites this paper
• A SURVEY OF HETEROLOGOUS EXPRESSION SYSTEMS FOR THE PRODUCTION OF BOVINE FOLLICLE STIMULATING HORMONE AND LUTEINIZING HORMONE

  2011cites this paper
• N-(5-substituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl) propanamides as glucokinase activators

  2011cites this paper
• Discovery and hit-to-lead optimization of novel allosteric glucokinase activators.

  2011cites this paper
• A new route to indoles via in situ desilylation–Sonogashira strategy: identification of novel small molecules as potential anti-tuberculosis agents

  2011cites this paper
• Alkynylation of N-(3-iodopyridin-2-yl)sulfonamide under Pd/C–Cu catalysis: a direct one pot synthesis of 7-azaindoles and their pharmacological evaluation as potential inhibitors of sirtuins

  2011cites this paper
• Transition metal mediated construction of pyrrole ring on 2,3-dihydroquinolin-4(1H)-one: synthesis and pharmacological evaluation of novel tricyclic heteroarenes.

  2011cites this paper
• Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.

  2011cites this paper
• Sequential coupling/desilylation-coupling/cyclization in a single pot under Pd/C-Cu catalysis: synthesis of 2-(hetero)aryl indoles.

  2011cites this paper
• Genetics and pathophysiology of neonatal diabetes mellitus

  2011cites this paper
• A Large-Scale Synthesis of Potent Glucokinase Activator MK-0941 via Selective O-Arylation and O-Alkylation

  2011cites this paper
• Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.

  2010cites this paper
• Hypoglycemic Effect Of Button ( Agaricus Bisporus ) And Oyster ( Pleurotus Ostreatus ) Mushrooms On Streptozotocin Induced Diabetic Mice

  2010cites this paper
• Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators.

  2010cites this paper